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Background: Previous studies have suggested that some children with autosomal 
recessive polycystic kidney disease (ARPKD) have growth impairment out of proportion to 
their degree of chronic kidney disease (CKD). The objective of this study was to systemat-
ically compare growth parameters in children with ARPKD to those with other congenital 
causes of CKD in the chronic kidney disease in Children (CKiD) prospective cohort study.
Methods: Height SD scores (z-scores), proportion of children with severe short stature 
(z-score < −1.88), rates of growth hormone use, and annual change in height z-score 
were analyzed in children with ARPKD (n = 22) compared with two matched control 
groups: children with aplastic/hypoplastic/dysplastic kidneys (n = 44) and obstructive 
uropathy (OU) (n = 44). Differences in baseline characteristics were tested by Wilcoxon 
rank-sum test or Fisher’s exact test. Matched differences in annual change in height 
z-score were tested by Wilcoxon signed-rank test.
results: Median height z-score in children with ARPKD was −1.1 [interquartile range 
−1.5, −0.2]; 14% of the ARPKD group had height z-score < −1.88, and 18% were 
using growth hormone. There were no significant differences in median height z-score, 
proportion with height z-score < −1.88, growth hormone use, or annual change in height 
z-score between the ARPKD and control groups.
conclusion: Children with ARPKD and mild-to-moderate CKD in the CKiD cohort have 
a high prevalence of growth abnormalities, but these are similar to children with other 
congenital causes of CKD. This study does not support a disease-specific effect of 
ARPKD on growth, at least in the subset of children with mild-to-moderate CKD.
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inTrODUcTiOn
Autosomal recessive polycystic kidney disease (ARPKD) is an inherited renal cystic disease that 
is typically diagnosed in infancy and leads to progressive chronic kidney disease (CKD) (1). 
Previous studies have reported growth impairment in approximately 25% of children with ARPKD 
(2, 3). In a subset of patients in prior reports, growth failure appeared to precede a significant 
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deterioration in glomerular filtration rate (GFR) and could not 
be readily attributed to other comorbidities, such as metabolic 
acidosis, anemia, primary growth hormone deficiency, malnu-
trition, liver dysfunction, or chronic lung disease (3, 4). Similar 
observations have been made in a mouse model of ARPKD, 
in which a subset of mice had growth impairment prior to 
the onset of significant renal disease (5). Some authors have 
speculated that ARPKD may have effects on growth independ-
ent of decreased kidney function, perhaps due to disturbances 
in the growth hormone/insulin-like growth factor (IGF)-1 axis 
or via decreased expression of growth hormone receptors in 
the liver (4). However, other authors have observed that growth 
impairment in patients with ARPKD does appear to correlate 
with decreased kidney function (2, 6).
The objective of this study was to characterize height deficits 
and linear growth in patients with ARPKD enrolled in the chronic 
kidney disease in children (CKiD) study, a prospective, longitu-
dinal investigation of children with mild-to-moderate CKD due 
to a wide range of diagnoses. We sought to test the hypothesis 
that children with ARPKD will have growth impairment out of 
proportion to their degree of kidney dysfunction, by comparing 
growth in children with ARPKD to those with other congenital 
causes of CKD.
MaTerials anD MeThODs
study Participants
Autosomal recessive polycystic kidney disease subjects and 
controls were selected from among those enrolled in CKiD, a lon-
gitudinal, prospective study of children with mild-to-moderate 
CKD. Complete eligibility criteria for CKiD have been published 
in detail elsewhere (7) and include age 1–16  years, estimated 
GFR of 30–90  mL/min/1.73  m2 calculated using the original 
Schwartz formula (8, 9) at enrollment, and absence of severe 
syndromic disease. The CKiD study protocol was approved by 
the Institutional Review Boards at all participating sites, and 
informed consent was obtained from all caregivers.
The current study was performed as a control-matched 
analysis within the CKiD cohort. All children enrolled in CKiD 
with a diagnosis of ARPKD were included in this analysis. 
Controls were obtained from two diagnostic groups with other 
congenital renal diseases: (1) aplastic/hypoplastic/dysplastic 
(A/H/D) kidneys and (2) obstructive uropathy (OU). Controls 
were matched to ARPKD subjects in a 2:1 ratio based on baseline 
ieGFR [GFR measured by plasma disappearance of iohexol 
(iGFR) or eGFR (10), if iGFR not available], age at study entry, 
and age at diagnosis. Matching was performed by calculating the 
Euclidean distance in 3-dimensional space (with baseline ieGFR, 
age at study entry, and age at diagnosis being the dimensions) 
between each of the 22 ARPKD subjects and each potential 
control (all subjects in CKiD with A/H/D or OU diagnoses, with 
each control group matched separately). The smallest distance 
(closest match) was then selected out of all possible matches; 
that control was removed, and then the procedure was repeated 
to choose closest matches until each ARPKD subject had two 
distinct matches.
growth Parameters
Height or length was determined at all CKiD study visits as the 
mean of two independent measurements, using a stadiometer 
for children >2 years old who are able to stand, or using a firm 
box in the supine position for children unable to stand (7). 
Age- and sex-specific height SD scores (z-scores) were calcu-
lated using United States (US) Centers for Disease Control and 
Prevention (CDC) growth charts of normative data (11). Growth 
hormone usage was ascertained at each visit using a standardized 
medication questionnaire. GFR was estimated yearly using the 
updated biomarker-based Schwartz formula (eGFR) (10) and 
was measured every other year using plasma disappearance of 
iohexol (iGFR) (12).
The primary outcomes examined in this study were height 
z-score, proportion of children with severe short stature (height 
z-score < −1.88), rates of growth hormone use at baseline, and 
annual change in height z-score. We also examined other covari-
ates that could have an influence on linear growth, including 
weight and body mass index (BMI, as indicators of nutritional 
status), pubertal (Tanner) stage, serum bicarbonate concentra-
tions, and use of bicarbonate supplementation [to evaluate 
degree of metabolic acidosis, which previous studies have shown 
can affect linear growth (13)], intact parathyroid hormone 
(iPTH) concentrations and use of phosphate binders (to assess 
for secondary hyperparathyroidism), hemoglobin [some studies 
have identified anemia as a risk factor for poor growth in CKD 
(14)], platelet count [to assess severity of portal hypertension in 
children with ARPKD (15)], albumin (to assess liver synthetic 
function), and need for intensive care unit and days of hospitali-
zation at birth (to assess for severity of other comorbidities such 
as pulmonary hypoplasia). Additional data regarding neonatal 
course, other comorbidities, growth hormone levels, or IGF 
binding protein levels were not available in this cohort. As an 
exploratory analysis, we also compared annual change in height 
z-score between users and non-users of growth hormone in all 
three groups.
statistical analysis
Demographic and clinical characteristics were reported as 
median (interquartile range, IQR) or number, n (%), for each 
group. Differences between the ARPKD group and each con-
trol group were tested by Wilcoxon rank-sum test or Fisher’s 
exact test. Annualized change in height z-score was calculated 
using individual regressions for each subject incorporating all 
available follow-up measurements. Matched differences were 
calculated as the difference between an ARPKD subject’s value 
and the average value of the two matched controls, and these 
distributions were tested for difference from 0 by Wilcoxon 
signed-rank test.
Since the sample size of ARPKD patients enrolled in CKiD 
was fixed, we did not perform power calculations to determine 
sample size. However, given the available sample size (n =  66 
total, with n = 22 ARPKD and n = 44 total controls), we would 
have been able to detect a difference in baseline height z-score 
of 0.83 or a difference in annual change in height z-score 
slope of 0.16.
TaBle 1 | Demographic, clinical, and growth characteristics of autosomal recessive polycystic kidney disease (arPKD) group compared to control groups 
with renal aplasia/hypoplasia/dysplasia (a/h/D) or obstructive uropathy (OU).
characteristic arPKD subjects (n = 22) a/h/D controls (n = 44) p OU controls (n = 44) p
Baseline characteristics
Tanner stage I 19 (90%) 35 (85%) 0.71 40 (91%) >0.99
Height z-scorea −1.1 [−1.5, −0.2] −0.8 [−1.7, 0.1] 0.97 −0.6 [−1.7, 0.3] 0.63
Height z-score < −1.88b 3 (14%) 8 (19%) 0.74 10 (23%) 0.52
Growth hormone use 4 (18%) 4 (9%) 0.42 6 (14%) 0.72
Weight z-scorea −0.2 [−1.0, 0.6] −0.3 [−1.2, 0.9] 0.85 −0.2 [−1.2, 0.7] 0.87
BMI z-score 0.4 [−0.1, 1.1] 0.2 [−0.5, 1.2] 0.70 0.5 [−0.1, 1.2] 0.85
Serum bicarbonate (mEq/L) 22 [20, 23] 23 [20, 25] 0.28 22 [20, 24] 0.70
Receiving bicarbonate supplementationb 3 (14%) 7 (16%) >0.99 4 (9%) 0.68
iPTH (pg/mL) 45 [30, 72] 49 [31, 99] 0.59 62 [29, 68] 0.47
Receiving phosphate binderb 5 (23%) 9 (20%) >0.99 8 (18%) 0.75
Hemoglobin (g/dL)a 11.7 [10.8, 12.4] 12.6 [12.0, 13.5] 0.001 12.6 [12.0, 13.7] 0.001
Platelets (×103/μL) 254 [149, 346] 274 [218, 320] 0.21 279 [232, 332] 0.14
Albumin (g/dL) 4.5 [4.4, 4.6] 4.4 [4.2, 4.6] 0.38 4.4 [4.3, 4.6] 0.24
ICU at birthb 10 (45%) 28 (64%) 0.19 23 (53%) 0.61
Days in hospital at birtha 3 [2, 21] 7 [3, 21] 0.24 5 [2, 30] 0.76
longitudinal characteristics
Annual change in height z-score
Among GH usersc −0.038 0.097 d 0.034 d
Among GH non-usersa −0.023 −0.028 −0.008
[−0.151, 0.094] [−0.116, 0.079] [−0.098, 0.080]
A/H/D, renal aplasia/hypoplasia/dysplasia; ARPKD, autosomal recessive polycystic kidney disease; BMI, body mass index; GH, growth hormone; iPTH, intact parathyroid hormone; 
OU, obstructive uropathy.
aMedian [interquartile range].
bNumber (% of total).
cMedian (insufficient data to calculate interquartile range).
dSample size too small for statistical comparison.
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resUlTs
Demographic and clinical Features
The baseline demographic and clinical features of the 22 ARPKD 
subjects and the A/H/D and OU control groups (n = 44 each) 
have been reported in our previous publication examining kidney 
disease progression in ARPKD subjects in the CKiD cohort (16). 
The ARPKD and control groups (A/H/D and OU) were success-
fully matched on baseline ieGFR, age at study entry, and age at 
diagnosis. For the ARPKD cohort, the mean age at study entry 
was 7.9  years and the mean baseline ieGFR was 43  mL/min/ 
1.73  m2. Twenty-seven percent of ARPKD patients were pre-
mature (<36  weeks gestation), and 18% had low birth weight 
(<2500  g). There were no significant differences between the 
ARPKD subjects and the two matched control groups for any of 
these parameters.
growth Parameters and 
Other covariates at Baseline
Baseline growth characteristics of the ARPKD group and the 
A/H/D and OU control groups are shown in Table 1. All three 
groups had height z-scores below the normal range compared 
with normative data for US children, but there were no significant 
differences in median height z-score among the three groups 
(ARPKD −1.1 vs. A/H/D −0.8, p = 0.97, ARPKD −1.1 vs. OU 
−0.6, p = 0.63). A large proportion of children in all three groups 
had severe short stature (height z-score less than −1.88, i.e., <3rd 
percentile), but there were no significant differences between the 
three groups (ARPKD 14% vs. A/H/D 19%, p = 0.74, ARPKD 
14% vs. OU 23% p = 0.52). The proportions of children using 
growth hormone were also similar between the three groups 
(ARPKD 18% vs. A/H/D 9%, p =  0.42, ARPKD 18% vs. OU 
14%, p = 0.72).
Examination of other covariates showed no significant dif-
ferences between the ARPKD group and the A/H/D and OU 
control groups in weight and BMI z-scores, pubertal (Tanner) 
stage, serum bicarbonate concentrations, use of bicarbonate 
supplementation, iPTH concentrations, and use of phosphate 
binders. The ARPKD group had lower median hemoglobin 
than the A/H/D and OU control groups (ARPKD 11.7 g/dL vs. 
A/H/D 12.6 g/dL, p = 0.001, ARPKD 11.7 g/dL vs. OU 12.6 g/dL, 
p = 0.001) (Table 1).
We assessed for severity of portal hypertension in the ARPKD 
group by comparing platelet counts across the groups. Although 
there were no significant differences in median platelet counts 
between the ARPKD and A/H/D and OU control groups 
(Table 1), a subset of the ARPKD group (6 out of 22, 27%) did 
have clinical evidence of portal hypertension, as evidenced by 
thrombocytopenia (platelet count < 150,000/μL). Median height 
z-score at baseline in ARPKD patients with thrombocytopenia 
(n =  6) was −0.39 [IQR −1.47, −0.16], compared with −1.28 
[IQR −1.48, −0.27] in those with normal platelet counts (n = 16). 
Although the small number of subjects precludes statistical 
analysis, the similarity of the interquartile ranges in the two 
groups suggests that there was no significant effect of portal 
FigUre 1 | annual change in height z-scores in children with 
autosomal recessive polycystic kidney disease (arPKD), aplastic/
hypoplastic/dysplastic kidneys (a/h/D), and obstructive uropathy 
(OU). Observed values are shown on the left and matched differences 
between the ARPKD group and each control group are shown on the right. 
p Values for matched differences between ARPKD and each control group 
are as shown. Boxes display the median and interquartile range of the 
observations.
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hypertension on baseline height. Serum albumin was similar 
between the ARPKD and control groups, indicating normal liver 
synthetic function (Table 1).
Although detailed clinical information regarding the presence 
of pulmonary hypoplasia at birth was not available, the ARPKD 
group had similar prevalence of needing ICU care at birth and 
similar durations of hospitalization compared to the A/H/D and 
OU control groups (Table 1).
longitudinal growth rates
Observed values for annual change in height z-score were −0.02 
[IQR −0.16, 0.10] in the ARPKD group, −0.02 [−0.11, 0.08] 
in the A/H/D group, and −0.01 [−0.07, 0.08] in the OU group 
(Figure 1). Examination of matched differences in annual change 
in height z-score showed no significant differences between the 
ARPKD and A/H/D groups (p = 0.52) or between the ARPKD 
and OU groups (p = 0.54).
We also explored the response to growth hormone in the 
ARPKD and control groups by examining annual change in 
height z-score in users and non-users of growth hormone. 
Although the small sample size precludes statistical analysis, it is 
interesting to note that the ARPKD subjects who were receiving 
growth hormone (n = 4) at baseline had lower annual change in 
height z-score (median −0.038) compared with those with A/H/D 
(n = 4, median 0.097) or OU (n = 6, median 0.034) (Table 1).
DiscUssiOn
In this study, we sought to determine whether children with 
ARPKD have deficits in height and linear growth beyond those 
attributable to decreased kidney function. We compared growth 
parameters in a well-characterized cohort of children with 
ARPKD in the CKiD cohort study to matched controls in two 
diagnostic groups, A/H/D and OU. These groups were chosen 
because they are also predominantly tubulointerstitial disorders 
and have a similar age of presentation as ARPKD. In a previous 
analysis, we have also shown that these two control groups have 
similar rates of GFR decline to children with ARPKD (16).
We found that children with ARPKD had a high prevalence 
of growth disorders, but the findings were overall similar to what 
was seen in children with other congenital causes of CKD. The 
ARPKD group had similar height z-scores, proportion of chil-
dren with severe short stature, and rates of growth hormone use at 
baseline and had similar rates of annual change of height z-score 
compared to children with A/H/D or OU. Height, weight, and 
BMI z-scores in all three groups were also comparable to those 
reported in children with non-glomerular disorders in the CKiD 
cohort as a whole (13). Body weight, BMI, and pubertal stage 
were similar among the three groups. All three groups had serum 
bicarbonate concentrations and iPTH within the normal range, 
with similar usage rates of bicarbonate supplementation and 
phosphate binders, indicating no significant metabolic acidosis 
or hyperparathyroidism.
The median platelet count in the ARPKD group was within the 
normal range, indicating overall low severity of portal hyperten-
sion in this group. Given the relatively mild liver phenotype in 
this group, we may not have been able to detect differences in 
growth attributable to portal hypertension. However, the simi-
larities in baseline height z-scores between ARPKD patients with 
vs. without thrombocytopenia were not suggestive of a strong 
effect of portal hypertension on growth in this cohort.
Overall, these data suggest that there is no disease-specific 
effect of ARPKD on linear growth beyond that attributable to 
CKD. As this is the first study to systematically compare ARPKD 
children with cohorts of patients with other congenital causes of 
CKD, it is likely that earlier observations of significant growth 
failure in children with ARPKD were attributable to other risk 
factors, such as early onset CKD, poor nutrition, prematurity, or 
other comorbidities. CKD during infancy and early childhood is 
a known risk factor for growth failure (17, 18), and many children 
with ARPKD present early in infancy. Much of the risk of growth 
failure in infants with CKD is due to inadequate nutrition (19), 
which children with ARPKD may be at particular risk for due to 
enlarged kidneys that can interfere with enteral feeding. Children 
with CKD who have abnormal birth history, including low birth 
weight, prematurity, and need for intensive care unit (ICU), are 
also at higher risk for short stature (20). A substantial proportion 
of children with ARPKD are born prematurely (27% in the current 
study), and many require ICU care and mechanical ventilation 
due to pulmonary hypoplasia (3), which may contribute further 
to their risk of growth failure.
Given prior reports showing relative under-utilization of 
growth hormone in children with CKD (13, 21), it is encouraging 
to note the relatively high rate of growth hormone use in this 
ARPKD cohort: 4 out of the 22 children (18%) reported growth 
hormone use, which actually exceeded the number of children 
with severe short stature at baseline [3 out of 22 (14%) with 
height z-score < −1.88]. As an exploratory analysis, we compared 
5Hartung et al. Growth in ARPKD
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 82
linear growth in children who were receiving growth hormone 
compared to those who were not. Although this analysis was sug-
gestive of a worse response to growth hormone in the ARPKD 
group compared with the A/H/D and OU control groups, our 
sample size was inadequate to draw any conclusions regarding 
response to growth hormone in ARPKD. A previous study has 
shown that children with ARPKD and short stature respond well 
to growth hormone therapy (4). Therefore, we believe children 
with ARPKD and growth failure should be offered growth 
hormone therapy in accordance with published guidelines for 
children with CKD (22).
Strengths of this study include accurate, standardized evalu-
ations of height, along with detailed clinical characterization of 
many covariates relevant for growth. This is also the first study to 
systematically compare linear growth in children with ARPKD 
to those with other causes of CKD, which allowed us to examine 
disease-specific effects of ARPKD on growth. The availability of 
longitudinal data also allowed us to compare linear growth rates 
over time. Limitations of this study include a relatively small sam-
ple size and the inclusion in CKiD of only children with mild-to-
moderate CKD. Thus, this population may not be representative 
of children with ARPKD as a whole. Despite the small sample 
size, we believe this is the largest cohort of ARPKD patients to 
undergo detailed characterization of growth with longitudinal 
measures. Therefore, description of growth parameters in this 
cohort adds to the limited body of literature on growth failure in 
children with ARPKD.
In conclusion, this study shows that children with ARPKD and 
mild-to-moderate CKD have a high prevalence of growth abnor-
malities, but these are comparable to children with other causes 
of CKD. Clinicians should, therefore, monitor linear growth 
closely in children with ARPKD and other causes of congenital 
CKD and should utilize strategies to improve growth, including 
ensuring adequate enteral nutrition and normal acid–base status 
and prescribing growth hormone as indicated.
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